Key result
Genetic testing identifies an etiology in ~17% of adults with primary hypercholesterolemia.
Cohort (n=1,682)
Answers are grounded in this paper and cite their sources.
Cohort study reveals identifiable genetic causes in 17.1% of adults with primary hypercholesterolemia, indicating modest overlap between clinical diagnostic criteria and genetic etiology.
We investigated monogenic and polygenic causes of hypercholesterolemia in a population-based cohort, excluding secondary hypercholesterolemia, and using an established framework to identify pathogenic variants. We studied 1682 individuals (50.2 ± 8.6 years, 41.3% males) from southeast Minnesota with primary hypercholesterolemia (low-density lipoprotein cholesterol (LDL-C) ≥155 mg/dl in the absence of identifiable secondary causes). Familial hypercholesterolemia (FH) phenotype was defined as a Dutch Lipid Clinic Network (DLCN) score ≥6. Participants underwent sequencing of LDLR, APOB, and PCSK9, and genotyping of 12 LDL-C-associated single-nucleotide variants to construct a polygenic score (PGS) for LDL-C. The presence of a pathogenic/likely pathogenic variant was considered monogenic etiology and a PGS ≥90th percentile was considered polygenic etiology. The mean LDL-C level was 187.3 ± 32.3 mg/dl and phenotypic FH was present in 8.4% of the cohort. An identifiable genetic etiology was present in 17.1% individuals (monogenic in 1.5% and polygenic in 15.6%). Phenotypic and genetic FH showed poor overlap. Only 26% of those who met the clinical criteria of FH had an identifiable genetic etiology and of those with an identifiable genetic etiology only 12.9% met clinical criteria for FH. Genetic factors explained 7.4% of the variance in LDL-C. In conclusion, in adults with primary hypercholesterolemia, 17.1% had an identifiable genetic etiology and the overlap between phenotypic and genetic FH was modest.
No takes yet. Share an insight, caveat, or question.
Saadatagah et al. (2021) conducted a cohort in Primary hypercholesterolemia (n=1,682). Genetic sequencing (LDLR, APOB, PCSK9) and LDL-C polygenic score vs. Phenotypic familial hypercholesterolemia (DLCN score >=6) was evaluated on Prevalence of identifiable genetic etiology (monogenic pathogenic variant or polygenic score >=90th percentile). Genetic testing identified a monogenic (1.5%) or polygenic (15.6%) etiology in 17.1% of adults with primary hypercholesterolemia, showing modest overlap with clinical FH criteria.
Synapse has enriched 10 related papers. Consider them for comparative context: